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Cronkhite-Canada syndrome (CCS) is a rare syndrome ﬁrst described in 1955. (1) Since then, 400 cases worldwide have been
reported in the literature. The disease is characterized by diﬀuse gastrointestinal polyposis, dystrophic changes of the ﬁngernails,
alopecia, cutaneous hyperpigmentation, diarrhea, weight loss, and abdominal pain. (2) The etiology is currently unknown, but an
autoimmune process is suspected. The workup is based on history and physical followed by imaging and endoscopy with biopsy
to conﬁrm gastrointestinal polyposis. The goal of treatment focuses on symptomatic management of the patient and nutritional
support.
Copyright © 2009 Kevin T. Kao et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Cronkhite-Canada syndrome (CCS) is a rare disease charac-
terized by the presence of diﬀuse gastrointestinal polyposis,
dystrophic changes in the ﬁngernails, alopecia, cutaneous
hyperpigmentation, diarrhea, weight loss, and abdominal
pain. Since 1955 when the syndrome was ﬁrst documented,
only about 400 cases have been reported worldwide. Here we
report a case of CCS in a woman of Filipino decent.
2. Case Presentation
2.1. History of Present Illness. M. N. is a 39-year-old Filipino
woman with a prior history of intestinal amebiasis, who
was referred to gastroenterology for evaluation of epigastric
pain.Hersymptomsbegantwomonthspriortopresentation
with 2 weeks of watery diarrhea for which she was treated
with metronidazole for presumed amebiasis. She reported
improvement of her diarrhea but subsequently developed
postprandial epigastric pain described as sharp in nature
and lasting for hours. She denied any fever, chills, nausea,
vomiting, dysphagia, or odynophagia. However, she did
reportdecreasingappetitewithearlysatietyanda9kgweight
loss over one month. She was initially evaluated by her
primary care physician, who prescribed famotidine for her
epigastric pain as well as hydrochlorothiazide for new onset
hypertension. Shortly after this visit, she noticed a signiﬁcant
amount of hair loss as well as hyperpigmentation of her
palms and soles. She worked at a jewelry store and denied
any substance abuse. Her family history was signiﬁcant for
one uncle who had colon cancer at an unknown age.
2.2. Physical Exam. Patient’s vital signs were unremarkable.
Her weight was 68kg and her height was 1.6 meters. Her
exam was signiﬁcant for diﬀuse alopecia and dystrophic
changes of her ﬁngernails (see Figure 1)a n dt o e n a i l s( s e e
Figure 2). There was also a faint hyperpigmentation of her
palms (see Figure 3) and soles. She had no lymphadenopathy
and her abdominal exam was unremarkable.
2.3. Laboratory. Her white blood cell count was 12.3
thousand cells/mL (normal range 4–11thousand cells/mL)
with an absolute eosinophil count of 233cells/mL. Her
hemoglobin was 15.2 gm/dL (normal range 12–16gm/dL)2 Gastroenterology Research and Practice
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and hematocrit was 44.5% (normal range 37–47%). Albu-
min was 3.2gm/dL (normal range 3.3–4.8gm/dL) and her
aminotransferases were normal.
2.4. Endoscopy Result. Esophagogastroduodenoscopy
revealed diﬀuse sessile polypoid lesions within the stomach.
They ranged between 4mm to 10mm in size with mucosal
edema. There did not appear to be a clear cut separation of
the polyps from the surrounding mucosa (see Figure 4). In
contrast to EGD, colonoscopy revealed the colonic mucosa
carpeted with sessile, strawberry-like polypoid lesions, 2mm
to 10mm in size, but with normal appearing surrounding
colonic mucosa (see Figure 5). Multiple polyps within
the stomach and colon were removed along with normal
appearing mucosa and sent to pathology.
2.5. Pathology. The colonic polyps revealed adenomatous
changes with stromal edema and dilated glands. The gastric
polyp biopsies showed focal hyperplastic features with
dilated glands. There was no evidence of eosinophilia (see
Figure 6).
2.6. Treatment Course. CCS was diagnosed based on a
combination of her symptoms, clinical features, and the
histopathology of polypoid lesions seen during endoscopy.
Additional blood work obtained including immunoglobulin
gamma 4 (IgG4) and Antineutrophilic cytoplasmic antibod-
ies(ANCAs)wereallwithinnormallimits.Duetoherweight
loss and poor appetite, nutritional therapy was initiated in
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the form of total peripheral nutrition (TPN). At one month
followup, the patient reported a weight gain of 6kg. She
also reported improvement of her alopecia, nail dystrophy,
and symptoms of diarrhea. TPN therapy was discontinued
after 2 months when she reported a rash around the infusion
site. Steroid therapy was discussed with the patient but
was declined. At her last followup, 12 months after the
initial diagnosis, she appeared to be in clinical remission.
Repeat endoscopy after 12 months also showed signiﬁcant
improvement in the number of polyps seen.
3. Discussion
Cronkhite-Canada syndrome is a rare systemic disease ﬁrst
reported in 1955 by Cronkhite and Canada [1]. Since then,
around 400 cases have been reported worldwide with the
Japanese contributing over 75% of these case reports [2].
Patients of European or Asian descent are most frequently
aﬀected. The estimated incidence of CCS is one per million
based on the largest study performed to date [3]. The mean
age of onset is estimated to be in the ﬁfth to sixth decade,
with a slight male predominance in 3 : 2 ratio [4].
The etiology of CCS is currently unknown. So far, there
is no strong evidence to suggest a familial predisposition.
Interestingly, cases have been associated with elevated antin-
uclear antibody (ANA) and IgG4 levels [2, 5, 6]. There
is also an association between CCS to hypothyroidism [7]
and various autoimmune diseases such as systemic lupus
erythematous, rheumatoid arthritis, and scleroderma, all ofGastroenterology Research and Practice 3
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which point toward an autoimmune etiology [8]. However,
others have reported mental stress and physical fatigue may
also contribute to the etiology [3].
The symptoms of CCS can vary, but classically it is
characterized by the presence of diﬀuse gastrointestinal
polyposis, dystrophic changes in nails, alopecia, cutaneous
hyperpigmentation, diarrhea, and weight loss. Other symp-
toms such as hypogeusia and xerostomia have also been
d e s c r i b e di nl i t e r a t u r e[ 9]. Endoscopic appearance of CCS
varies according to current literature. Gastric mucosa has
been described as being thickened hypertrophic gastric folds
mimicking Menetrier’s disease to atrophic appearing with
polypoid lesions [10]. Colonic polyps have been character-
ized as sessile and “strawberry like” in one study [11].
The optimal treatment of CCS is currently unknown due
in part to its rarity. Nutritional support aimed at improving
electrolytes, vitamin, and mineral deﬁciencies can rarely
induce complete remission as seen in our patient. In fact,
current literature favors a combination therapy based on
nutritional support and corticosteroids [12]. We believe
that TPN therapy in combination with partial bowel rest
may have provided crucial nutritional support allowing the
disease process to enter remission. Other therapies such
as antihistamine receptor antagonist agents and cromolyn
sodium have also been used as supplement therapy in
cases where degranulating eosinophils and mast cells are
seen on biopsy [13]. One Case report has also suggested
improvement of CCS after eradication of Helicobacter Pylori
infection [14].Thetotaltreatmentperiodisnotwelldeﬁned,
varying from 6 to 12 months of combination therapy.
Numerous complications can rise from CCS, with the
most notable being the development of malignancy. This
c a nb ea sh i g ha s1 5 %[ 15]. Both gastric and colorectal
cancers have been reported, with sigmoid colon and the
rectum being the most common initial site of cancer [16].
Unfortunately, due to the rarity of this disease, optimal
screening protocols have not been developed, although
annual endoscopic surveillance has been widely practiced.
The long-term prognosis is quite poor according to early
studies. One study is reporting a 55% mortality rate in their
55 patient case study [8]. However, with improvement in
medical therapy and increased recognition of the syndrome,
theprognosisisnowthoughttobebettercomparedtoearlier
case reports.
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